News

We are extremely proud that our central involvement in designing, execution and analysis of of the Telix ZIRCON pivotal phase III study was recently recognised in The Lancet Oncology.This prospective, open-label, multicentre study evaluated the clinical utility of...

This summer we welcome our first two trainees. We look forward to seeing them learn and grow!!

We are proud to announce that the dosimetry software QDOSE® designed by us and our development partner Quantinm AB will now become part of a commercial partnership with Telix. Telix intends to integrate the platform into its therapeutic radiopharmaceutical programmes...

Summer 2024 is coming up and as every year we are returning to the SNMMI 2024 in Toronto, Canada on June 8-11. Our two General Managers, Dr. Andreas Kluge and Andreas Fintelmann, and the CEO of ABX-CRO INC, Moritz Kallerhoff, will be there again accompanied by our...

This year we will start our conference activities in Santiago, Chile for the 7th Theranostics World Congress. From March 22 to 24 you can find us at booth #A06 and talk with Dr. Andreas Kluge and Andreas Fintelmann, our General Managers, about how ABX-CRO can help you...

Prostate cancer awareness month may already be over, but men's health remains an important topic. We are therefore most pleased to announce that ABX-CRO was chosen to collaborate with Curasight in a phase 2 study to improve the diagnosis of prostate cancer. The...